Global CDMO Expansion VectorBuilder’s multinational footprint with operations in North America, Europe, China, Japan, South Korea, and Australia, plus planned Chicago life sciences facility expansion, signals ongoing capacity growth. This creates cross-border collaboration opportunities for BD teams to offer scalable gene delivery solutions, contract manufacturing partnerships, and regionalized support for multinational customers.

Clinical Advancement Partnerships Recent news shows strategic partnerships to advance gene delivery solutions for ex vivo cell engineering and a plasmid DNA therapeutic vaccine in late-stage development. Target potential customers in biotech and pharma seeking validated delivery platforms, manufacturing partnerships, and turnkey support for late-stage programs.

Product Ecosystem Momentum Major update to VectorBee and a strong emphasis on end-to-end gene delivery solutions indicate continued product improvement and broad applicability for research and clinical uses. Opportunities exist to upsell advanced software tools, training, and customization services to labs needing enhanced sequence analysis and optimization workflows.

Strategic Partnerships Alliances with MaxCyte for ex vivo cell engineering and potential co-development of new delivery systems position VectorBuilder as a collaborator of choice for integrative platform solutions. Leverage these relationships to pitch bundled offerings combining delivery plasmids, device compatibility, and regulatory-friendly manufacturing support.

Financial Health & Scale With revenue in the mid-range tens of millions and substantial funding, VectorBuilder demonstrates financial viability and investment capacity to support enterprise-level projects, long-term collaborations, and large-scale manufacturing initiatives. Use this to approach prospective customers with multi-year program proposals and favorable terms.